Indian Pharma Company Makes Headway In The US: Cipla To Acquire Avenue TherapeuticsCipla Head Office. (Alyssa Banta/Newsmakers)

Indian drug and pharma company, Cipla Limited, has agreed to buy Avenue Therapeutics Inc, a speciality pharma company based out of the US. The $215 million (Rs 15.6 billion) deal will be completed in two phases, as reported by Business Standard.

“Our investment in and proposed acquisition of Avenue establishes our presence in the speciality institutional business in the US. The novel intravenous drug delivery method of Tramadol addresses extremely crucial and hitherto unmet needs in pain management. This investment is in keeping with our stated intention to build a speciality pipeline in the US market,” Umang Vohra, Global CEO of Cipla noted. Tramadol is a unique analgesic being developed by Avenue to treat pain in adults.

The Indian drugmaker has been making serious headway in the US markets. It recently obtained USFDA’s approval for its drug, Valganciclovir. These tablets are used to treat viral eye infection in AIDS patients. The US drug regulator also gave its nod to Diclofenac Sodium Topical Gel, which is used to treat osteoarthritis of joints such as the knees and hands.

Aurobindo Pharma Ltd., an India company, also agreed to buy the generics arm of Novartis’ US business for $1 Billion in September 2018.

Also Read:

Gujarat Is The Top State In India For Manufacturing Quality Medicines

Indian Pharma Sector Should Move From Generics To Innovation

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber